Leucine

Leucine

SCHEMBL1479588

CC(C)C[C@H](N)C(=O)O.COC(=O)[C@@H]1CCCN1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.49
SLC1A3 P43003 3/20 0.41
SLC1A2 P43004 3/20 0.41
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
MMP3 P08254 1/20 0.37
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
SLC1A1 P43005 3/20 0.36
PRCP P42785 1/20 0.35
KDM4E B2RXH2 1/20 0.35
DPP7 Q9UHL4 2/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
DPP4 P27487 1/20 0.34
DPP8 Q6V1X1 1/20 0.34
DPP9 Q86TI2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL1479587 1.00 SLC7A5 (0.49) SLC7A5SLC1A3SLC1A2CYP3A4CYP2D6
Leucine SCHEMBL6463328 0.87 SLC7A5 (0.44) SLC7A5SLC1A3SLC1A2CYP3A4CYP2D6
Leucine SCHEMBL17113855 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
Leucine SCHEMBL17113857 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
Leucine SCHEMBL5060410 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
Leucine SCHEMBL139231 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
Leucine SCHEMBL756554 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
D-Leucine SCHEMBL1537225 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
Leucine SCHEMBL139230 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP
Leucine SCHEMBL29092653 0.86 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1PRCP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008094846-A1 REVERSIBLE ROOM-TEMPERATURE IONIC LIQUIDS GEORGETOWN UNIVERSITY (US) 2008-08-07 WO claimed
US-9433895-B2 Reversible room-temperature ionic liquids GEORGETOWN UNIVERSITY (US) 2016-09-06 US disclosed
US-20140120013-A1 Reversible Room-Temperature Ionic Liquids GEORGETOWN UNIVERSITY (US) 2014-05-01 US disclosed
US-8574453-B2 Reversible room-temperature ionic liquids GEORGETOWN UNIVERSITY (US) 2013-11-05 US disclosed
US-20110076214-A1 Reversible Room-Temperature Ionic Liquids Georgetown University Office of Technology Commercialization (US) 2011-03-31 US disclosed
WO-2008094846-A1 REVERSIBLE ROOM-TEMPERATURE IONIC LIQUIDS GEORGETOWN UNIVERSITY (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110076214-A1 Reversible Room-Temperature Ionic Liquids TRMT1L, TRRAP, RCOR3 SLC7A5 994/4885SLC1A3 1801/4885SLC1A2 1422/4885
US-20140120013-A1 Reversible Room-Temperature Ionic Liquids TRMT1L, TRRAP, RCOR3 SLC7A5 994/4885SLC1A3 1801/4885SLC1A2 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.